B细胞淋巴瘤2家族成员与肉瘤：在异质性疾病中的一个有前途的靶点。
B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease.
发表日期：2023
作者：
Rui Caetano Oliveira, João Gama, José Casanova
来源：
Disease Models & Mechanisms
摘要：
靶向B细胞淋巴瘤2（Bcl-2）家族蛋白已成为血液系统恶性肿瘤治疗的主要支柱，能够提高整体生存率。Bcl-2家族在凋亡调控中是主要的参与者，引起了研究人员对实体肿瘤治疗的兴趣。肉瘤是一组异质性疾病，包括多种实体，具有较高的发病率和死亡率，并且可用的特异性治疗方法很少。肉瘤的治疗基于白金方案，结果各异，且病情进展严重时效果较差。不同的肉瘤实体数量众多，使得治疗标准化以及进行临床试验变得困难。Bcl-2家族成员调节剂在体外和体内模型中展现出了有希望的结果，并且可能是一种有效的选择，特别是在与化疗结合使用时。本文对这些结果进行了回顾，并探讨了在肉瘤中使用Bcl-2家族成员抑制剂的可能性。© 作者 2023.
Targeting the B-cell lymphoma 2 (Bcl-2) family proteins has been the backbone for hematological malignancies with overall survival improvements. The Bcl-2 family is a major player in apoptosis regulation and, has captured the researcher's interest in the treatment of solid tumors. Sarcomas are a heterogeneous group of diseases, comprising several entities, with high morbidity and mortality and with few specific therapies available. The treatment for sarcomas is based on platinum regimens, with variable results and poor outcomes, especially in advanced lesions. The high number of different sarcoma entities makes treatment standardization as well as the performance of clinical trials difficult. The use of Bcl-2 family members modifiers has revealed promising results in in vitro and in vivo models and may be a valid option, especially when used in combination with chemotherapy. In this article, a revision of these results and possibilities for the use of Bcl-2 family members inhibitors in sarcomas was performed.© The Author(s) 2023.